A nosh, for those of you deficient in culinary indulgences, is another way of saying snack. And nosh, we must. You will, of course, relate to the analogy that there is much to chew on, yes? So grab a cup of something hot, or a bottle of something cold, and take a bite…

The widower of a New Jersey woman who died while using the Nuvaring contraceptive is suing Schering-Plough and Organon Biosciences, which made the device. Robert Bozicev claims Nuvaring, which his wife used for six months, says she collapsed, had trouble breathing and died of a blood clot. His lawyer says she had no risk factors and was in good health. The suit charges known health risks were concealed.

Pfizer is closing its Groton manufacturing facility and laying off 80 workers. “The facility has ceased operating, a Pfizer spokeswoman tells The Hartford Courant. “This is the only part of the Groton site we have closed.” In 2006, the drugmaker announced its plans to phase out manufacturing at the site by the end of 2008, which would result in the loss of 300 positions.

Two former CVS execs accused of paying off a state senator were arraigned for a second time after federal prosecutors presented more details about the bribery allegations against them, the Associated Press reports. John Kramer and Carlos Ortiz, both former CVS vp’s, are awaiting trial on federal fraud, bribery and conspiracy charges. They have pleaded not guilty to charges they paid former state senator John Celona to defeat bills CVS opposed.

Cephalon won FDA approval to sell Treanda for treating chronic lymphocytic leukemia (CLL), a blood cancer that usually afflicts people averaging 70 years old. About 15,000 new cases of CLL will be diagnosed in the US this year, Reuters writes. Cephalon, which sells the Provigil narcolepsy drug, hopes Treanda will create a bigger presence in the cancer market. Wall Street predicts sales could reach between $300 million and $500 million.

A skin patch helped boost a bird flu vaccine so well that people appear to be protected by a single dose, according to Iomai, a biotech. The so-called adjuvant patch, which is designed to be used with an injected vaccine, could help stretch supplies during a pandemic, Reuters writes, adding that current approved vaccines against the H5N1 avian flu require two doses to be fully effective. Of those tested, 73 percent had what is considered a protective immune response.